Three Rivers, Sandoz Ribavirin Generics Approved; Labeling "Carves Out" Use With PEG-Intron
This article was originally published in The Pink Sheet Daily
Executive Summary
Par launches Three Rivers' Ribasphere at a 10% discount to Schering's Rebetol. FDA awards "shared exclusivity" to Three Rivers and Sandoz. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
You may also be interested in...
Par/Three Rivers Ribavirin ANDA Is "Approvable"
Launch of the Rebetol generic is "on the near-term horizon," Par CEO Tarriff says. Approval is contingent on resolution of labeling issues.
FDA Stands By Generic "Shared Exclusivity" Policy During Paxil Appeal
The agency will continue to award 180-day exclusivity to multiple ANDA filers "when applicable" while it appeals a ruling invalidating this approach for paroxetine generics. "Shared exclusivity" issues raised in the Paxil case could come up again if they are not resolved by the appeals court, FDA says.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.